InvestorsHub Logo
Followers 1
Posts 178
Boards Moderated 0
Alias Born 08/24/2017

Re: A deleted message

Thursday, 08/31/2017 6:56:48 PM

Thursday, August 31, 2017 6:56:48 PM

Post# of 41259
I believe the Amedica problems are one major hurdle but I am taking about the Zimmer issues...

https://seekingalpha.com/article/4102689-zimmer-biomet-needs-experienced-leader

Zimmer isnt in a position for any acquisition any time soon. Earliest would be 2nd or 3rd Q 2018.


Although he led the Company through a series of acquisitions that led to substantial growth, Dvorak's departure followed a string of recent bad news for the Company. In November of last year, the FDA issued an extensive Form 483 that detailed what the inspector felt were deficiencies in Zimmer Biomet's processes. These findings resulted in delayed shipment of certain products during Q4 of last year. The Company has two manufacturing facilities, in Puerto Rico and Montreal, with FDA warning letters that remain pending.

The Company issued a recall in December for one of their shoulder implant systems, which covered 3,662 devices, due to a higher risk of fracture. Zimmer Biomet faced another recall earlier this year for a spinal fusion stimulator that contained potentially unacceptable levels of cytotoxic chemicals. Fortunately, this recall only impacted 33 devices in the U.S.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News